Analyst Bullish Targets and Buy Calls
Key Questions
What recent analyst upgrades has AbbVie received?
BofA upgraded AbbVie, adding to actions by UBS and Goldman Sachs (GS raised PT to $244 Neutral from $240). Piper Sandler maintains Buy at $294, with others like Canaccord at $262.
What is the consensus analyst rating and price target for AbbVie?
Consensus is Moderate Buy with 78% Buy ratings and average price targets of $253-256. Guggenheim has targets around $229-$249.
Why are analysts bullish on AbbVie?
Analysts highlight immunology strength from Skyrizi and Rinvoq offsetting the Humira cliff, plus neuroscience and oncology ramps. Valuation at 14x forward PE and PEG of 0.73 supports the view.
Is the current dip in AbbVie stock seen as a buying opportunity?
Yes, analysts emphasize the dip as an entry point due to strong fundamentals post-Humira pivot. Upgrades from BofA, UBS, and GS reinforce bullish outlook.
What price targets have key analysts set for AbbVie?
Piper Sandler: $294 Buy; Canaccord: $262; Guggenheim: $249/$229/$249; GS: $244 Neutral; consensus $253-256. These reflect confidence in growth drivers.
BofA upgrade adds to UBS/GS (GS $244 Neutral from $240)/Piper Buy $294/Canaccord $262/Guggenheim $249/$229/$249 PTs; consensus $253-256 Moderate Buy (78% buys). Emphasize immunology strength offsetting Humira cliff, neuro/onc ramps at 14x fwd PE, PEG 0.73; dip as entry.